

Senate Order 13 (Murray Motion)
List of Grant contracts active during 2020-2021 Financial Year - Cancer Australia

Grant/Funding Recipient	Grant Agreement / Contract Purpose (Subject Matter)	Activity Id/ Contract Registration number/ Record Id/ SAP Id	Activity Start Date	Anticipated Activity End Date	Agreement Value (GST inclusive) (Amount of)
ANZ Breast Cancer Trials Group	Capacity building support to the Breast Cancer Trials (BCT) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	CA 1718 172	29/06/2018	01/03/2022	\$1,919,039.10
Australian Leukaemia and Lymphoma Group	Capacity building support to the Australasian Leukaemia and Lymphoma Group (ALLG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	CA 1718 170	29/06/2018	01/03/2022	\$1,925,000.00
Australian National University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: AUTO-CHECK study: Molecular determinants of autoimmunity and immune related adverse events in advanced cancer patients treated with immune checkpoint inhibitors. APPID: 1130330-COOK	CA-G1516/74	25/04/2017	24/01/2022	\$574,009.00
Breast Cancer Network Australia	Funding Agreement with BCNA in relation to the Supporting Women in Rural Areas Diagnosed with Breast Cancer Program	CA 1415 017	11/07/2017	26/10/2021	\$2,616,935.00
Canberra Hospital Foundation	Supporting people with cancer Grant initiative - Pathways to wellbeing for Aboriginal and Torres Strait Islander people with cancer in the ACT and surrounding regions	GA176982	30/06/2021	30/06/2024	\$132,000.00
Cancer Council NSW	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Hide and seek with hereditary cancer: Improving detection of colorectal cancer patients with a high risk of Lynch syndrome. APPID: 1123924-TAYLOR	CA-G1516/70	30/06/2017	29/09/2021	\$579,140.00
Central Adelaide Local Health Network	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: A new gene modification strategy for generating optimised CAR-T cells for therapy of glioblastoma. APPID: 2003828-BROWN	2003828	01/10/2021	30/12/2024	\$600,000.00
Central Adelaide Local Health Network (CALHN)	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Predicting and improving anti-tumour responses to immunotherapy in advanced cancer patients. APPID: 1186306-EBERT	1186306	01/06/2020	31/08/2023	\$560,142.00
Circular Head Aboriginal Corporation	Supporting people with cancer Grant initiative - Supporting Aboriginal people affected by cancer in a remote Tasmanian community: Developing the cultural and clinical pathway (Healing journeys)	GA176999	30/06/2021	30/06/2024	\$127,600.00
Derbarl Yerrigan Health Services Aboriginal Corp	Supporting people with cancer Grant initiative - Wangkiny moorditch nyin (good talking circle/sitting down)(Yarning both ways)	GA177002	30/06/2021	30/06/2024	\$132,000.00
Flinders University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: Targeting CDK9 in lethal prostate cancer. APPID: 2001432-SELTH	2001432	30/06/2021	29/09/2024	\$459,811.00
Flinders University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Increasing resilience and reducing smoking for lower socio-economic groups. APPID: 1182598-WARD	1182598	01/06/2020	26/01/2024	\$553,820.00
Flinders University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Personalising treatment and surveillance for colorectal cancer: prognostication with the circulating tumour-derived methylated DNA markers BCAT1 and IKZF1 AppID: 1161720 - SYMONDS	CA 1819 103	01/06/2019	31/08/2022	\$553,196.00
Flinders University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: Finding My Way-Advanced: Can a web-based psychosocial intervention improve mental quality of life for women with metastatic breast cancer? APPID: 2000514-BEATTY	2000514	01/01/2022	31/03/2025	\$545,259.00
La Trobe University	Priority-driven Collaborative Cancer Research Scheme international (PdCCRSi) 2018: Tackling Breast Cancer Heterogeneity for the Complete Eradication of Metastases. APPID: CCR19606878-MERINO	CCR19606878	15/05/2019	15/08/2022	\$300,000.00
La Trobe University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Improving Immune Checkpoint Treatment of Colorectal Cancer by STAT3 inhibition APPID: 1144460-ERNST	CA-G1718-33	30/06/2018	29/08/2021	\$598,677.00
La Trobe University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: A multistage multicentre international randomised trial of Conventional care Or Radioablation (stereotactic body radiotherapy) for Extra-cranial oligometastatic disease in lung, breast and prostate cancer (CORE). APPID: 1104569-Foroudi	CA-G1516/32	28/06/2016	30/09/2021	\$430,563.00
Menzies School of Health Research	Supporting people with cancer Grant initiative - Optimising equitable access to cancer research participation for Aboriginal and Torres Strait Islander people: Development of culturally-responsive resources to guide informed decisionmaking	GA176978	30/06/2021	30/06/2024	\$119,150.00
Monash University	Capacity building support to the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	CA 1718 173	29/06/2018	01/03/2022	\$1,750,000.00
Monash University	Capacity building support to the Melanoma and Skin Cancer Trials (MASC; formerly ANZMTG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	CA 1718 175	29/06/2018	01/03/2022	\$1,750,000.00
Monash University	Investing in medical Research - fighting childhood cancer: LGG Avastin study	CA 1718 044	27/10/2017	31/08/2023	\$506,419
Monash University	Investing in medical Research - fighting childhood cancer: AIM BRAIN trial	CA 1718 036	27/10/2017	31/08/2021	\$1,742,898
Monash University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019 international: Checkpoint receptors expressed by dendritic cells- do they play a role in immunotherapies? APPID: 20-0300-O'KEEFE	20-0300	01/02/2020	01/05/2023	\$241,027.00

Monash University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Translating Colorectal Cancer Organoids into Patient Care APPID: 1145907-ABUD	CA-G1718-06	16/04/2018	15/07/2021	\$597,557.00
Mujaay Ganma Foundation Aboriginal Corporation	Supporting people with cancer Grant initiative - Country and Culture - Caring and Healing	GA176995	30/06/2021	30/06/2024	\$125,697.00
Queensland University of Technology	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Development of a translational bioengineered microenvironment model to advance pre-clinical acute myeloid leukaemia research AppID: 1159637 - BRAY	CA 1819 146	30/06/2019	29/09/2022	\$133,017.00
Queensland University of Technology	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Circulating Tumour Cells: Clinical Application in Head and Neck Cancers. APPID: 1145657-PUNYADEERA	CA-G1718-11	29/06/2018	28/09/2022	\$599,756.00
Queensland University of Technology	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Humanized rat models - the next frontier in pre-clinical osteosarcoma research APPID: 1181919-McGOVERN	1181919	01/01/2021	31/03/2023	\$131,710.00
The Council of the Queensland Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: The harms and benefits of sun exposure: striking the right balance. APPID: 2000511-GORDON	2000511	14/06/2021	13/09/2024	\$528,984.00
The Kids Cancer Project Pty Ltd	For the provision of services to establish and promote an annual Childhood Brain Cancer Awareness Day	CN3632111	17/09/2019	30/06/2022	\$110,000.00
The University of Newcastle	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Obesity epidemic fuelling the surge of endometrial cancers: Elucidating the role and targeting of molecular signals involved in fat and endometrial cancer cross talk. APPID: 1187542-TANWAR	1187542	31/03/2020	28/05/2023	\$600,000.00
The University of Sydney	Capacity building support to the Australasian Leukaemia and Lymphoma Group (AGITG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	CA 1718 169	29/06/2018	01/03/2022	\$1,750,000.00
The University of Sydney	Capacity building support to the Thoracic Oncology Group of Australasia (TOGA; formerly ALTG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	CA 1718 171	29/06/2018	01/03/2022	\$1,750,000.00
The University of Sydney	Capacity building support to the Australia New Zealand Gynaecological Oncology Group (ANZGOG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	CA 1718 174	29/06/2018	01/03/2022	\$1,750,000.00
The University of Sydney	Capacity building support to the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	CA 1718 176	29/06/2018	01/03/2022	\$1,750,000.00
The University of Sydney	Capacity building support to the Cooperative Trials Group for Neuro-Oncology (COGNO) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	CA 1718 178	29/06/2018	01/03/2022	\$1,750,000.00
The University of Sydney	Capacity building support to the Psycho-oncology Co-operative Research Group (PoCoG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	CA 1718 179	29/06/2018	01/03/2022	\$1,727,995.00
The University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: P3BEP Trial: Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours: An Australian-Led, International Randomised Trial. AppID: 1159837-GRIMISON	CA 1819 116	30/06/2019	29/09/2022	\$600,000.00
The University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Improving tumour targeting and delineation in lung cancer radiotherapy AppID: 1161748-O'BRIEN	CA 1819 182	30/06/2019	29/09/2023	\$600,000.00
The University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: The ECHO trial: Exercise during Chemotherapy for Ovarian cancer AppID: 1158566-HAYES	CA 1819 122	14/05/2019	13/08/2022	\$597,443.00
The University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Personalised targeted therapy for adolescent and young adult medulloblastoma patients AppID: 1165910-HOVEY	CA 1819 115	30/06/2019	29/09/2022	\$167,168.50
The Walter and Eliza Hall Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: Improving safety and efficacy of chimeric antigen receptor (CAR)-T cell therapies. APPID: 2002983-CALL	2002983	01/01/2022	31/03/2025	\$600,000.00
The Walter and Eliza Hall Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: Designing personalised treatment strategies for KEAP1-mutant lung cancer. APPID: 2003127-Best	2003127	30/06/2021	29/09/2023	\$200,000.00
Trans Tasman Radiation Oncology Group	Capacity building support to the Trans Tasman Radiation Oncology Group (TROG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	CA 1718 180	29/06/2018	01/03/2022	\$1,925,000.00
Trans Tasman Radiation Oncology Group	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Novel Integration of New prostate radiation schedules with adjuvant Androgen deprivation (NINJA) AppID: 1158455-MARTIN	CA 1819 112	30/06/2019	29/09/2022	\$600,000.00
University of Adelaide	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Novel co-extinction strategies for treatment of prostate cancer APPID: 1138766-BUTLER	CA-G1718-08	16/04/2018	15/01/2022	\$596,409.00
University of Adelaide	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2012: A pharmacodynamic study of the heat shock protein 90 (Hsp90) inhibitor, AUY922, in high-risk, localised prostate cancer. APPID: 1050880-BUTLER	CA-A 1213/28	01/05/2013	31/03/2022	\$360,977.00
University of Melbourne	Capacity building support to the Australia and New Zealand Sarcoma Association (ANZSA; formerly ASSG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	CA 1718 177	29/06/2018	01/03/2022	\$1,750,000.00

University of Melbourne	Capacity building support to the Primary Care Collaborative Cancer Clinical Trials Group (PC4) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	CA 1718 181	29/06/2018	01/03/2022	\$1,750,000.00
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019 international: Checkpoint receptors expressed by dendritic cells- do they play a role in immunotherapies? APPID: 663175-DAWSON	663175	01/01/2021	31/03/2024	\$670,500.00
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: SCRIPT: an RCT of genomic-based stratified colorectal cancer screening in primary care. APPID: 1183338-EMERY	118338	30/06/2020	29/09/2023	\$551,184.00
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Integrative approaches to identifying the causes of familial breast cancer. APPID: 1188547-CAMPBELL	1188547	27/04/2020	26/07/2023	\$547,825.00
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: The Preclinical Validation of Radio-labelled Girentuximab as a Theranostic Agent in Metastatic Colorectal Cancer. APPID: 1184859-HOLLANDE	1184859	23/03/2020	22/06/2023	\$506,210.00
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: A combined immuno-molecular biomarker for early breast disease. APPID: 2002944-GORRINGE	2002944	14/06/2021	13/09/2024	\$498,695.00
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: Augmenting CXCR3 ligand production to enhance the trafficking of T cells in solid cancers. APPID: 2001335-BEAVIS	2001335	01/06/2021	30/08/2024	\$497,672.00
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: SCORE: Shared care of Colorectal cancer survivors – A randomised controlled trial of hospital-based follow up versus shared hospital / general practice follow up for survivors of colorectal cancer (CRC) AppID: 1158397-JEFFORD	CA 1819 107	01/04/2019	30/11/2022	\$479,375.00
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Stereotactic Ablative Radiotherapy (SABR) as a New Precision Treatment Option in Kidney Cancer APPID: 1139464-SIVA	CA-G1718-10	30/03/2018	29/07/2022	\$589,082.00
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Functional precision medicine for aggressive childhood cancers. APPID: 1185313-KAVALLARIS	1185313	01/10/2020	30/12/2023	\$596,955.00
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Decoding the Dark Matter of the High-Risk Paediatric Cancer Genome AppID: 1165556-COWLEY	CA 1819 104	07/05/2019	06/08/2022	\$377,048.00
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Functional precision medicine for aggressive childhood cancers. APPID: 1188234-HABER	1188234	01/01/2021	31/03/2024	\$347,705.00
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting the NAD pathway as a new therapeutic strategy for high-risk leukaemia in children AppID: 1164865-HENDERSON	CA 1819 110	20/05/2019	19/08/2022	\$321,045.00
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS)2018: Therapeutic targeting of a novel self-renewal signalling in leukaemia stem cells AppID: 1165516-WANG	CA 1819 111	30/06/2019	31/03/2023	\$300,000.00
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Application of gene-silencing nanodrugs to inhibit medulloblastoma growth. APPID: 1184840-McCARROLL	1184840	26/02/2020	25/05/2023	\$298,554.00
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting Polo-like kinase 1 as a novel therapeutic opportunity for Diffuse Intrinsic Pontine Gliomas AppID: 1165708-ZIEGLER	CA 1819 109	28/05/2019	27/05/2022	\$278,281.00
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Microtubule deregulation in lung cancer and therapeutic strategies APPID: 1141485-KAVALLARIS	CA-G1718-14	29/03/2018	31/03/2022	\$592,694.00
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: The contribution of rare alleles to non high grade serous ovarian cancer APPID: 1147276-RAMUS	CA-G1718-30	30/06/2018	29/08/2021	\$597,632.00
University of NSW	Supporting people with cancer Grant initiative - BRIDGES-4AYA: Returning to Employment and Study for Adolescents and Young Adults with cancer	GA176979	30/06/2021	30/06/2024	\$120,000.00
University of Queensland	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: Long-read genetic and epigenetic profiling in lung cancer for precision medicine. APPID: 2003170-FAULKNER	2003170	30/06/2021	29/09/2024	\$567,596.00
University of Queensland	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Exploiting CDK4/6 inhibition to treat medulloblastoma AppID: 1165777-WAINWRIGHT	CA 1819 113	30/06/2019	29/09/2022	\$196,206.00
University of Queensland	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Development of oxytocin receptor specific tracers for improved breast cancer management APPID: 1146504-ALEWOOD	CA-G1718-31	30/06/2018	29/08/2021	\$400,000.00
University of Queensland	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Streamlining lung cancer diagnosis through genomic testing of cytology smears APPID: 1147067-FIELDING	CA-G1718-32	30/06/2018	30/09/2022	\$400,000.00
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019:Immuno-metabolic biomarkers to predict treatment response in metastatic prostate cancer APPID: 1188642-HORVATH	1188642	01/01/2021	31/03/2024	\$600,000.00
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Phase II clinical trial of the PARP inhibitor, olaparib, in HR- deficient advanced breast and ovarian cancer in women without inherited BRCA1 or BRCA2 mutations. APPID: 1128740-SJOQUIST	CA-G1516/71	17/04/2017	30/06/2023	\$600,000.00
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: ICON9: A phase 3 randomised trial of cediranib and olaparib maintenance in patients with relapsed platinum sensitive ovarian cancer. APPID: 1100619-MILESHKIN	CA-G1516/34	15/04/2016	31/03/2022	\$600,000.00

University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2014: ANZMTG 02.12 RADICAL - RAdiotherapy (RT) or Imiquimod (ImiQ) in Complex lentigo maLigna (LM). APPID: 1083221-GUITERA	CA-G1415/51	01/05/2015	31/12/2021	\$600,000.00
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: The PEARL trial: Palliative care Early in Advanced Lung cancers. APPID: 1101882-MILESHKIN	CA-G1516/37	18/04/2016	30/09/2021	\$598,099.00
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: High Precision Radiotherapy: Dual Cardiac and Respiratory Motion Management. APPID: 1123068-O'BRIEN	CA-G1516/55	30/06/2017	30/09/2021	\$597,325.50
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: The Liver Ablative Radiotherapy with KIM (LARK) Clinical Trial APPID:1143778-KEALL	CA-G1718-09	01/05/2018	30/07/2021	\$583,371.00
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Life and Health After Childhood Cancer: a national data linkage cohort study. APPID: 1187545-NASSAR	1187545	01/06/2020	31/08/2023	\$569,900.00
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Remove the Mask: Reducing Anxiety and Distress for Head and Neck Cancer Radiotherapy Patients. APPID: 1180776-KEALL	1180776	30/06/2020	29/09/2023	\$568,445.00
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: Phase II randomised placebo-controlled, double blind, multisite study of acetazolamide versus placebo for management of cerebral oedema in recurrent and/or progressive HGG requiring treatment with dexamethasone – The ACED trial. APPID: 1098932-AGAR	CA-G1516/24	01/04/2016	30/03/2022	\$524,365.00
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 Trial). APPID: 1100306-SHANNON	CA-G1516/25	01/03/2016	30/12/2021	\$497,544.00
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Molecular drivers of malignancy and response to targeted treatment in chemotherapy-resistant low-grade serous ovarian cancer APPID: 1142697-DE FAZIO	CA-G1718-15	19/03/2018	28/12/2021	\$492,411.00
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: ASCOLT: ASpirin for Dukes C and high risk B COLorecTal cancer. An International, Multi-centre, Double Blind, Randomised Trial. APPID: 1182824-SEGLOV	1182824	13/05/2020	12/08/2023	\$465,000.00
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Empowering the clinician-patient-carer trio: RCT of novel online education modules to facilitate effective family carer involvement in oncology. APPID: 1146383-JURASKOVA	CA-G1718-05	19/03/2018	18/03/2023	\$296,601.00
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: Developing a Patient-Reported Symptom Index for Non-muscle Invasive Bladder Cancer. APPID: 1103036-PATEL	CA-G1516/19	30/06/2016	30/09/2021	\$233,158.50
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma: the CODEL trial APPID: 1130594-HOVEY	CA-G1516/67	30/06/2017	29/09/2023	\$221,534.04
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: The SPAR Trial: a randomised placebo-controlled phase 2 trial of simvastatin with preoperative chemoradiation for rectal cancer. APPID: 1125958-ACKLAND	CA-G1516/85	30/06/2017	31/03/2023	\$148,857.00
University of Technology Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: A phase III wait-listed RCT of a novel targeted inter-professional clinical education intervention to improve cancer patients' reported pain outcomes. APPID: 1127011-PHILLIPS	CA-G1617/83	30/06/2017	30/09/2021	\$342,483.00
University of Technology Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Randomised, double-blind, placebo-controlled phase III trial of oral melatonin for the prevention of delirium in hospital in people with advanced cancer. APPID: 1127727-AGAR	CA-G1516/54	01/04/2017	30/09/2021	\$599,820.00
University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Mixed radiotherapy fractionation: modulating tumour microenvironment to stimulate and enhance immunotherapy AppID: 1163065-EBERT	CA 1819 123	01/05/2019	30/07/2022	\$597,521.00
University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019 international: Improving anti-cancer therapy by stromal remodelling. APPID: 21-057-GANSS	21-0257	01/03/2021	01/06/2024	\$214,398.53
University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: Reprogramming the tumour microenvironment to improve immunotherapy. APPID: 2002303-HE	2002303	30/06/2021	29/09/2023	\$200,000.00
University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Intraoperative immunotherapy to prevent relapse in soft tissue sarcoma. APPID: 1184331-LESTERHUIS	1184331	01/04/2020	30/06/2022	\$197,525.00
University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Sensitising medulloblastoma to conventional treatment using kinase inhibitors APPID: 1147153-GOTTARDO	CA-G1718-16	01/05/2018	31/07/2021	\$530,428.00
University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Measuring breast density in younger women to inform primary prevention and early detection of breast cancer. APPID: 1147677-STONE	CA-G1718-12	08/03/2018	31/03/2022	\$592,636.00

University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Reprogramming the Tumour Microenvironment with the use of Nanomedicines for the Treatment of Pancreatic Cancer. AppID: 1126736-PHILLIPS	CA-G1516/69	30/06/2017	30/11/2021	\$247,983.25
Walter & Eliza Hall Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting BCL-2 in estrogen receptor positive breast cancer AppID: 1165878-LINDEMAN	CA 1819 117	29/04/2019	28/07/2022	\$599,562.00
Walter & Eliza Hall Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Designing Chimeric Antigen Receptor T cells for Diffuse Intrinsic Pontine Glioma AppID: 1164657-JENKINS	CA 1819 137	06/05/2019	05/08/2022	\$592,388.00
Walter & Eliza Hall Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting multidrug resistance protein 1 (MDR1) enhances the efficacy of Smac-mimetic-based therapy in Acute Myeloid Leukaemia AppID: 1162023-BRUMATTI	CA 1819 118	01/06/2019	31/08/2022	\$361,023.00
Waminda - South Coast Womens Health and Welfare Aboriginal Corporation	Supporting people with cancer Grant initiative - The Waminda Linking Shoalhaven's Cancer Care Services project	GA176997	30/06/2021	30/06/2024	\$132,000.00
Western Sydney University	Supporting people with cancer Grant initiative Supporting the transition from hospital cancer treatment to wellness for women from Chinese, Vietnamese and Arabic backgrounds: a tailored stepped supportive care program	GA176989	30/06/2021	30/06/2024	\$118,823.00